Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $178.00 by Analysts at Royal Bank of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price decreased by Royal Bank of Canada from $179.00 to $178.00 in a research report report published on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other research reports. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Stock Up 0.2 %

Shares of Jazz Pharmaceuticals stock opened at $143.53 on Wednesday. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of 20.22, a P/E/G ratio of 1.04 and a beta of 0.56. The company’s 50 day moving average price is $126.28 and its 200-day moving average price is $118.79. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 5,053 shares of company stock valued at $617,442 in the last quarter. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently modified their holdings of the stock. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth about $25,000. Quadrant Capital Group LLC raised its position in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth about $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.